Literature DB >> 6272965

Long-term T-cell-mediated immunity to Epstein-Barr virus.

A B Rickinson, D J Moss, L E Wallace, M Rowe, I S Misko, M A Epstein, J H Pope.   

Abstract

Mesh:

Substances:

Year:  1981        PMID: 6272965

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  58 in total

1.  Varicella-zoster virus-specific cytotoxic T lymphocytes (Tc): detection and frequency analysis of HLA class I-restricted Tc in human peripheral blood.

Authors:  J K Hickling; L K Borysiewicz; J G Sissons
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

2.  Different patterns of Epstein-Barr virus gene expression and of cytotoxic T-cell recognition in B-cell lines infected with transforming (B95.8) or nontransforming (P3HR1) virus strains.

Authors:  R J Murray; L S Young; A Calender; C D Gregory; M Rowe; G M Lenoir; A B Rickinson
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

3.  An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants.

Authors:  S R Burrows; I S Misko; T B Sculley; C Schmidt; D J Moss
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

Review 4.  Immune regulation of Epstein-Barr virus (EBV): EBV nuclear antigen as a target for EBV-specific T cell lysis.

Authors:  D J Moss; I S Misko; T B Sculley; A Apolloni; R Khanna; S R Burrows
Journal:  Springer Semin Immunopathol       Date:  1991

5.  Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies.

Authors:  C Schmidt; S R Burrows; T B Sculley; D J Moss; I S Misko
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

6.  Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes.

Authors:  I Bourgault; A Gomez; E Gomard; J P Levy
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

7.  Epstein-Barr virus recombinants with specifically mutated BCRF1 genes.

Authors:  S Swaminathan; R Hesselton; J Sullivan; E Kieff
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

Review 8.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

9.  Defective control of Epstein-Barr virus-infected B cell growth in patients with X-linked lymphoproliferative disease.

Authors:  N Yasuda; P K Lai; J Rogers; D T Purtlo
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

10.  Epstein-Barr serology in immunodeficiencies: an attempt to correlate with immune abnormalities in Wiskott-Aldrich and Chediak-Higashi syndromes and ataxia telangiectasia.

Authors:  E Vilmer; G M Lenoir; J L Virelizier; C Griscelli
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.